-
公开(公告)号：US20130289084A1
公开(公告)日：2013-10-31
申请号：US13979127
申请日：2012-01-11
IPC分类号： A61K31/4184 , A61K31/28
CPC分类号： A61K31/537 , A61K9/0019 , A61K9/2009 , A61K9/2054 , A61K31/28 , A61K31/4178 , A61K31/4184 , A61K31/80 , A61K45/06 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.
摘要翻译： 本发明涉及药物组合物，其包含：（a）至少一种血管紧张素受体阻断剂或其药学上可接受的盐，和（b）至少一种趋化因子受体途径抑制剂或其药学上可接受的盐。 本发明还涉及药物组合物，其包含：（a）至少一种血管紧张素受体阻断剂或其药学上可接受的盐; 和（b）抑制除趋化因子受体以外的趋化因子受体途径的成分的至少一种趋化因子受体途径抑制剂或其药学上可接受的盐。 描述包含药物组合物的口服缓释药物组合物，以及包含该药物组合物的可注射持续释放药物组合物。 本发明还涉及包含药物组合物的片剂，胶囊，可注射悬浮液和用于肺或鼻输送的组合物。 还描述了：用于评估药物组合物的功效的方法; 用于评估药物组合物的抑制或部分抑制活性的方法; 用于治疗，改善或预防病症或疾病的方法，包括向受试者施用治疗有效量的药物组合物; 以及该药物组合物用于制备用于治疗疾病的剂型的用途。
-
公开(公告)号：US20120100130A1
公开(公告)日：2012-04-26
申请号：US13260530
申请日：2010-03-26
IPC分类号： A61K39/395 , G01N33/567 , C12N5/071 , C07K19/00 , C07K16/42
CPC分类号： G01N33/74 , C07K14/7158 , G01N33/6863 , G01N2333/7158 , G01N2500/04
摘要： A hetero-dimeric or hetero-oligomeric receptor, comprising at least one chemokine receptor subunit associated with at least one angiotensin receptor subunit.
摘要翻译： 异二聚体或异低聚受体，其包含与至少一个血管紧张素受体亚基相关联的至少一个趋化因子受体亚单位。
-
公开(公告)号：US09314450B2
公开(公告)日：2016-04-19
申请号：US13979127
申请日：2012-01-11
IPC分类号： A61K31/41 , A61K31/4184 , A61K31/4178 , A61K31/537 , A61K31/80 , A61K45/06 , A61K9/00 , A61K9/20 , A61K31/28
CPC分类号： A61K31/537 , A61K9/0019 , A61K9/2009 , A61K9/2054 , A61K31/28 , A61K31/4178 , A61K31/4184 , A61K31/80 , A61K45/06 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof, and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising: (a) at least one angiotensin receptor blocker or a pharmaceutically acceptable salt thereof; and (b) at least one chemokine receptor pathway inhibitor or a pharmaceutically acceptable salt thereof which inhibits a component of the chemokine receptor pathway other than the chemokine receptor. Oral sustained release pharmaceutical compositions comprising the pharmaceutical composition, as well as injectable sustained release pharmaceutical compositions comprising the pharmaceutical composition are described. The invention further relates to tablets, capsules, injectable suspensions, and compositions for pulmonary or nasal delivery comprising the pharmaceutical composition. Also described are: methods for assessing the efficacy of the pharmaceutical composition; methods for assessing the inhibition or partial inhibition activity of the pharmaceutical composition; methods for the treatment, amelioration or prevention of a condition or disease comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition; and the use of the pharmaceutical composition for the manufacture of a dosage form for the treatment of a disease.
摘要翻译： 本发明涉及药物组合物，其包含：（a）至少一种血管紧张素受体阻断剂或其药学上可接受的盐，和（b）至少一种趋化因子受体途径抑制剂或其药学上可接受的盐。 本发明还涉及药物组合物，其包含：（a）至少一种血管紧张素受体阻断剂或其药学上可接受的盐; 和（b）抑制除趋化因子受体以外的趋化因子受体途径的成分的至少一种趋化因子受体途径抑制剂或其药学上可接受的盐。 描述包含药物组合物的口服缓释药物组合物，以及包含该药物组合物的可注射持续释放药物组合物。 本发明还涉及包含药物组合物的片剂，胶囊，可注射悬浮液和用于肺或鼻输送的组合物。 还描述了：用于评估药物组合物的功效的方法; 用于评估药物组合物的抑制或部分抑制活性的方法; 用于治疗，改善或预防病症或疾病的方法，包括向受试者施用治疗有效量的药物组合物; 以及该药物组合物用于制备用于治疗疾病的剂型的用途。
-
-
搜索结果
3 条记录 (耗时 0.014 秒)
